Cantor Fitzgerald Maintains Overweight on ADMA Biologics, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has maintained an Overweight rating on ADMA Biologics and increased the price target from $8 to $10.
May 10, 2024 | 3:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald's upgrade of the price target for ADMA Biologics from $8 to $10 while maintaining an Overweight rating suggests a positive outlook on the stock's future performance.
The increase in price target by a reputable analyst firm like Cantor Fitzgerald typically signals a strong conviction in the company's future growth prospects and financial health. This can lead to increased investor confidence and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100